NGen Funds Rapid Manufacturing Scale-up of COVID-19 Vaccine Candidate

Nova Scotia based IMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, announced that Canadian government agencies will contribute up to CA$4.75 million to advance Phase 1 clinical development of its vaccine candidate, DPX-COVID-19, for the prevention of COVID-19 infection caused by the novel coronavirus SARS-COV-2.

Read More_>

About Crissy Wright

Crissy Wright is the Community Facilitator at the Manufacturing Innovation Network (MIN).


Subscribe to our e-mail newsletter to receive updates.

No comments yet.

Leave a Reply